ArticleInternational journal of hepatology2013
Molecular classification of hepatocellular adenomas.
Article in International journal of hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Hepatocellular Carcinoma Precursor Lesions: From Pathological Basis to Risk Stratification and Precision Intervention.Journal of hepatocellular carcinoma · 2026Review
- Review
- Hepatocellular adenomas: recent updates.Journal of pathology and translational medicine · 2021Review
- Hepatic adenomatosis in a young woman with non-familial maturity-onset diabetes of the young type 3.Canadian liver journal · 2021Article
- Cystic degeneration of hepatic adenoma: a rare complication of hepatic adenoma.BJR case reports · 2018Article
- Molecular classification of hepatocellular adenomas: impact on clinical practice.Hepatic oncology · 2018Review
- Expression of liver fatty acid binding protein in hepatocellular carcinoma.Human pathology · 2016Article
- [Hepatocellular tumours in noncirrhotic liver tissue].Der Pathologe · 2015Review
- Current concepts in the immunohistochemical evaluation of liver tumors.World journal of hepatology · 2015Review
- Benign solid tumors of the liver: management in the modern era.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015Review
- Treatment of Hepatic Adenomatosis.Current hepatology reports · 2015Article
- STAT3 in hepatocellular carcinoma: new perspectives.Hepatic oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular adenomas (HCAs) are benign tumors developed in normal liver most frequently in women before menopause. HCAs lead to diagnostic pitfalls and several difficulties to assess the risk of malignant transformation in these young patients. Recent advances in basic knowledge have revealed a molecular classification related to risk factors, pathological features, and risk of transformation in hepatocellular carcinoma. Three major molecular pathways have been identified altered in specific HCA subgroups that are defined by either (1) inactivation of hepatocyte nuclear factor 1A (HNF1A) transcription factor, (2) activation of the WNT/β-catenin by CTNNB1 mutations, or (3) activation of the IL6/STAT3 pathway by somatic mutation of IL6ST, GNAS, or STAT3. Here, we will review the different molecular classes of HCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.